Filing Details
- Accession Number:
- 0001562180-20-002275
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-03-06 20:03:18
- Reporting Period:
- 2020-03-04
- Accepted Time:
- 2020-03-06 20:03:18
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 897448 | Amarin Corp Plc | AMRN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1199637 | F John Thero | C/O Amarin Pharma, Inc. 440 Us Highway 22 Bridgewater NJ 08807 | President And Ceo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Disposition | 2020-03-04 | 200,000 | $15.99 | 2,480,441 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted in 2017 by the Reporting Person in accordance with the requirements for such plans described in the Company's Annual Report on Form 10-K.
- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- The price reported in Column 4 is a weighted average price. These shares were sold, pursuant to a Rule 10b5-1 trading plan previously adopted in 2017 by the Reporting Person, in multiple transactions at prices ranging from $15.74 to $16.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- Please see the section titled "Remarks" below for additional information.
Billionaire Hedge Funds
